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1. Introduction 
Mitochondr ia l  oxidat ive phosphory lat ion  (OXPHOS)  in 
adult humans,  under  normal  physio logical  condit ions,  cov-  
ers more than 80% of  the energy needs, the remain ing  
* Corresponding author. Fax: +39 80 5478429; e-mail: 
papabchm @ cimedoc.uniba.it. 
be ing met by glycolysis.  An  adult man with daily energy 
needs of  some 3000 kcal turns over  400 mol  of  ATP.  
OXPHOS capacity varies f rom tissue to t issue and so do 
the ATP  needs. The brain is the organ with the h ighest  
demand for aerobic ATP  product ion,  account ing,  with only 
2% of  the body mass, for 20% of  total oxygen consump-  
t ion at rest [1], but also heart, muscle,  k idney and en- 
docr ine systems rely h ighly on OXPHOS capacity [2]. 
OXPHOS capacity of mammal ian  cells changes in the 
0005-2728/96/$15.00 Copyright © 1996 Elsevier Science B.V. All rights reserved. 
PII S0005-2728(96)00077-  1 
88 S. Papa/Biochimica et Biophysica Acta 1276 (1996) 87-105 
life-span. In fetal tissues anaerobic glycolysis represents 
the major source of cellular ATP, the capacity of oxidative 
phosphorylation being relatively low [3,4]. At birth a clear 
onset of oxidative phosphorylation ccurs as a result of the 
rapid induction of mitochondrial biogenesis [5-7]. The 
capacity of OXPHOS attains a maximum level in young 
and adult mammals. The capacity of OXPHOS can, how- 
ever, vary in response to changes in energy demand through 
adaptive response of mitochondrial ctivity and biogenesis 
to physical activity [8,9]. 
Morphological [10,11] and biochemical observations 
[12-18] indicate a progressive decline with age of the 
mitochondrial respiratory systems in human tissues. This, 
together with the finding of defective OXPHOS and the 
occurrence of deletion and point mutations of mitochon- 
drial DNA in neuromuscular disorders and other degenera- 
tive diseases [2], suggests that progressive decrease with 
age of mitochondrial function is critical for the functional 
decline of brain, heart, muscle, endocrine systems and 
other post-mitotic tissues, which is associated with aging 
[2,19,20]. This review aims to provide a concerted picture 
of the different changes in OXPHOS taking place in the 
life span, from their genetic and molecular basis, to in vivo 
'monitoring' of OXPHOS and physiopathological implica- 
tions of OXPHOS changes. 
2. The mitochondrial OXPHOS system 
The mitochondrial enzyme-system of OXPHOS consists 
of five oligomeric protein complexes (Table 1) [2,21-33]. 
Complexes I [22-24] and II [25] collect electrons from 
NADH and succinate, respectively, and pass them to 
ubiquinone which is oxidized by ubiquinone cytochrome-c 
oxidoreductase (complex III) [26,27] and cytochrome-c 
oxidase (complex IV) [26,28-30]. With the exception of 
D-loop 
ND 
10,4 kb deletion 
Complex I Complex V 
Complex III Transfer RNA 
Complex IV Ribosomal RNA 
Fig. 1. The mitochondrial genome of mammalian cells. For details see text, Table 1 and Refs. [2] and [36]. The external lines indicate mtDNA deletions 
detected in human tissues in diseases (see Table 2). 
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complex II, each of these complexes couples electron flow 
to proton pumping and the ensuing protonmotive force is 
utilized by complex V (FoF  l H + ATP synthase) [31-33] 
to form ATP from ADP and Pj [34,35]. Each of the five 
complexes is made up of different subunits and complexes 
I, II, III and IV have multiple redox-active prosthetic 
groups (Table 1). Thirteen of the subunits of complexes I,
III, IV and V are encoded by the mitochondrial genome 
(mtDNA), all the remaining by nuclear genes [2,36]. 
mtDNA also encodes for two rRNAs and all the tRNAs 
involved in mitochondrial protein synthesis [2,36] (Fig. 1). 
Recent developments in understanding the mechanism 
of mtDNA replication and transcription have led to the 
identification of essential nucleus-encoded components 
[37-39]. The mitochondrial proteins synthesized in the 
cytoplasm are imported in mitochondria, processed and 
assembled in the mature enzymes by complex systems 
[40,41]. 
Mitochondrial biogenesis, involving the concerted ex- 
pression of two different genomes [37,39,42], is likely to 
be particularly susceptible to mutagenic and other harmful 
agents. Since all the structural mitochondria] genes code 
for subunits of the OXPHOS enzymes, the protein factors 
controlling mitochondrial biogenesis at the level of replica- 
tion, transcription and translation of nuclear and mitochon- 
drial genes [37,39] and the proteins responsible for recog- 
nition by mitochondria, import, processing and assembly 
into the functional complexes of cytosolic precursor pro- 
teins [40,41], have to be coded by nuclear genes. Nuclear- 
encoded activating factors have been identified which are 
involved in the coordinated expression of the nuclear and 
mitochondrial genes of OXPHOS enzymes [39,42]. There 
are, however, observations indicating that in human cells, 
at least, the nuclear and mitochondrial transcription factors 
do not share regulatory polynucleotide sequence lements 
[43]. 
A human cell contains several hundred mitochondria 
and each mitochondria contains 5-10 mtDNA genomes 
[2]. This relative abundance of mtDNA copies implies that 
rearrangement and base substitution mutations in an mt 
gene in germline and/or  somatic cells have to affect a 
substantial proportion of its copies so as to result in a 
phenotypic decline of OXPHOS and, when more pro- 
nounced, in an overt pathological condition [20]. 
Integration of mitochondrial OXPHOS with cytosolic 
energy metabolism and ATP utilizing processes is main- 
tained by a series of nuclear-encoded substrate transloca- 
tors in the inner mitochondrial membrane [44,45], among 
which the adenine [46], phosphate [47] and pyruvate [48] 
translocators play a central role. A defect in one of these 
translocators can also result in a decline of the OXPHOS 
capacity and in a pathological situation. 
3. Developmental changes of OXPHOS 
In mammalian tissues the enzymes of OXPHOS un- 
dergo definite changes in the transition from fetal to 
post-natal life. Fetal tissues are characterized by high 
levels of glycolytic enzymes [3] and a high rate of glycoly- 
sis [3,4,49]. At birth, mammalian tissues adapt themselves 
to the aerobic extrauterine environment with a switch from 
fetal anaerobic glycolysis to neonatal OXPHOS [4-7,50]. 
This change is associated with post-natal induction of 
Regulatory genes 1 
Promoter ~ NRF 2/ 
mt TFA q NRF1 GABP 
~ ~ ~ ~ ~ ~ .  Transcription of 
Ets-1 Ets-2 II I ~  F,B subunits 
mRNA --  b t n, ~ Transcription of / ~ .~ Nuclear eu uni s 
A ~ COX subunits ~ l 
~ ;~ ~ ~ Import 
~ ~  mt RNAprocessing - e $ -I 
mt TFB~ RNA AS~ me y . ~  
~HtMT(~ A / ~ ~"  mt :ubunits 
' I 77  ox . .os  
~ *  mt mRNA / ~  . . 
. . . . . .  polymerase ' ...--, ~ mt mmure ¢omp,exe$ 
t~P- L~ ~ ribosomes 
d loop promote~~ ~ RNA binding 
protein (GDH) 
Fig. 2. Scheme describing the interplay of regulatory genes coding for transcription factors of nuclear and mitochondrial OXPHOS genes, mtTFA (HMG, 
high mobility group) and mtTFB, nuclear transcription factors of mt genome [37], HSP and LSP heavy and light strand promoters in the mt genome 
[36,37]. Ets-1 and Ets-2, nuclear genes of the Ets family [68] coding for transcription factors of cytochrome-c oxidase (COX) [71] and F]13 subunit of FoF I
ATP synthase [70]. NRF-I and NRF-2/GABP [73,74] nuclear genes coding for transcription factors of COX, other espiratory enzymes, Ft!3 subunit 
[56,73,84] and mTFA [72]. 
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mitochondrial biogenesis (mitochondrial differentiation and 
mitochondrial proliferation) [6,7]. During fetal rat-liver 
development, nuclear-encoded mitochondrial mRNAs ac- 
cumulate in a translationally repressed state [51] while the 
amount and activity of the corresponding enzymes are 
particularly low [52]. Within one hour after birth, an 
activation of translation initiation of nuclear encoded 
mRNA occurs in the liver without changes in the amount 
of the translational machinery [50]. A marker of the trans- 
lational activation of these mRNAs is represented by the 
13-subunit of F 1 ATPase whose level increases in the first 
hour after birth [50]. It has been proposed that the perinatal 
enhancement of translational efficiency of the mRNA for 
the 13Fj subunit could be due to changes in the 
poly(A)+RNA fraction or in the reporter template itself 
[52]. The translationally-repressed 13F 1 mRNA which ac- 
cumulates in fetal liver is relatively stable, the post-natal 
translationally-activated 13F~ mRNA is, instead, more 
readily susceptible to decay [53]. In fact, there seems to be 
a direct relationship between the stability of this mRNA 
and protein synthesis [53]. 
A role in the translational efficiency and stability of 
mRNAs seems to be played by matrix dehydrogenases 
which contain RNA binding sites [54,55]. 
At variance with mitochondrial differentiation, which is 
associated with rapid post-natal translational activation of 
mRNAs already accumulated in the fetal liver, mitochon- 
drial proliferation, which is a more prolonged phe- 
nomenon, depends on the transcriptional ctivity of genes 
[53]. The 13F l nuclear gene is under complex transcrip- 
tional regulation. This includes an NRF-2 responsive le- 
ment [56] (Fig. 2), an enhancer element shared by cy- 
tochrome-Q and subunit E la  of pyruvate dehydrogenase 
[57], nuclear factors interacting with overlapping promoter 
elements [58] and thyroid hormone responsive lements 
[59]. 
The dramatic activation at birth of the expression in 
liver of nuclear genes coding for subunits of OXPHOS 
enzymes, as well as of mitochondrial genes [60], which is 
exerted at both transcriptional and post-transcriptional 
level, makes perinatal development a most useful model 
for the study of regulation of mitochondrial biogenesis. 
It is worth mentioning here that rapidly growing tumour 
cells have a reduced number of mitochondria nd exhibit a 
decrease in OXPHOS activity and enhancement of anaero- 
bic and aerobic glycolysis [61,62]. Contrary to the expecta- 
tion, this reduction in the number of mitochondria has been 
found to be associated, both in neoplastic tissues [63,64] 
and in viral and cellular oncogene transformed cell cul- 
tures [65-67], with enhanced levels of mRNA transcripts 
of nuclear and mitochondrial OXPHOS genes. Interest- 
ingly enough, among the OXPHOS genes induced in tu- 
mour cells there is the 13F~ gene whose transcript level is 
particularly high in fetal liver [7]. Thus, in neoplastic 
transformation the expression of OXPHOS genes seems to 
experience a fetal shift. Induction of OXPHOS genes in 
transformed cells could represent an abortive compen- 
satory mechanism in response to events which ultimately 
lead to a reduction in the number of mitochondria nd in 
the overall OXPHOS capacity of neoplastic ells. 
It is tempting to speculate that certain critical genetic 
elements and/or systems involved in the regulation of 
mitochondrial biogenesis are affected, though in the oppo- 
site way, in both development and transformation. A role 
in this respect could be played by ets proteins [68]. These 
proteins, which resemble the V-ets oncogenes [69], with 
which they share an ets-domain interacting specifically 
with purine-rich DNA sequences, have been found in 
different species and are involved in the regulation of gene 
expression in a variety of biological processes [68]. The ets 
proteins regulate the expression of the 13F1 gene [70] and 
subunits 4 and 5a of cytochrome-c oxidase [71] and are 
considered to belong to the elements involved in the 
coordinate enhanced expression of OXPHOS genes in 
response to proliferative signals [39,70-74] (Fig. 2). It has 
also been found that a mitochondrial elongation factor 
similar to the E. coli EF-Tu and the mitochondrial EF-Tu 
of S. cerevisiae is overexpressed in a variety of tumours of 
human and animal origin [75]. 
4. Adaptation to exercise and OXPHOS 
The number and volume of mitochondria relative to 
other cell constituents and the activity of OXPHOS en- 
zymes are not fixed in adult animals and humans but 
appear to vary with the pattern of activity performed by 
the organs. This is clearly exemplified by the skeletal 
muscle where the number of mitochondria per cell and the 
specific activity of respiratory enzymes increase with exer- 
cise [8,76,77] and the same pattern has been observed in 
the heart [78]. No information is available for other organs 
but it is likely that adaptive response of mitochondria to 
the functional activity load is a general phenomenon in 
higher eukaryote cells. The content of mitochondria per 
cell varies also from type to type of striated muscle. 
Cardiac myocites contain up to 40% of their cell volume 
as mitochondria in small mammals, whilst type I skeletal 
fibers of humans contain as low as 1-2% of their cell 
volume as mitochondria nd the mitochondrial content 
varies even within the same general type of muscle [79]. 
All this shows that vertebrate organisms have mechanisms 
which regulate the number of mitochondria and the content 
and activity of OXPHOS enzymes, at least in contractile 
tissues, in response to molecular signals generated in mes- 
enchymal cells, as they differentiate into mature tissue 
cells, or in differentiated muscle and other tissues in 
response to changes in the functional activity. 
A prolonged increase in the contractile activity of skele- 
tal muscle in laboratory animals, as that produced for 
weeks by daily exercise, induces a dramatic (nearly one 
order) enhancement in the level and activity of OXPHOS 
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enzymes and reduction in glycolytic enzymes [8,76,77]. 
Similar and more rapid and even larger increases in OX- 
PHOS enzymes are observed upon chronic electrical stim- 
ulation of specific muscles via the motor nerves in rabbits 
[80,81]. It should be noted that the induction of functional 
OXPHOS enzymes in the muscle requires the activation of 
the coordinate expression of nuclear and mitochondrial 
OXPHOS genes in the absence of cell division. 
Increased contractile activity has been found in rabbit 
[82,83] and men [84] to enhance the level of mitochon- 
drially encoded RNAs (cytochrome b, subunit 1 of com- 
plex IV, subunit ND6 of complex I, 16S rRNA), as well as 
of nuclear encoded RNAs (subunit 4 of complex IV, [3F l
subunit, succinate dehydrogenase) (see also Ref. [85]). The 
increase in the mRNA transcripts of the nuclear genes 
encoding mitochondrial proteins was, however, smaller 
than the observed enhancement of the mRNA transcripts 
of the mitochondrial genes. Prolonged exercise was also 
found to be associated with enhancement of the concentra- 
tion of mtDNA, whereas nuclear DNA content was not 
changed [82,84,86]. This observation suggests that amplifi- 
cation of the mitochondrial genome relative to nuclear 
DNA is an important feature of the enhanced expression of 
OXPHOS enzymes in highly oxidative tissues [84,86]. 
Critical elements for concerted induction of expression 
of nuclear and mitochondrial genes encoding for OXPHOS 
enzymes could be represented by the nuclear respiratory 
factors (NRF) 1 and 2 which have been found to activate 
[72] the human mitochondrial transcription factor A gene 
(see Fig. 2). In fact, mtTFA seems to provide an important 
control point for both mitochondrial copy number and 
transcriptional ctivity [37]. NRF-I and NRF-2 also acti- 
vate, on the other hand, the expression of a number of 
nuclear genes which encode cytochrome-c, subunits for 
Table 2 
mtDNA mutations in mitochondrial diseases 
three of the five respiratory complexes and the mitochon- 
drial RNA processing RNA [73,74] (Fig. 2). NRF-2 was 
identified as an activator of cytochrome oxidase gene 
expression i  Hela cells, from which it has been purified to 
near homogeneity [71]. This multisubunit activator shares 
homologous ubunits with the mouse GA binding protein, 
a member of the family of the ets protein [68], involved in 
the expression of Herpes simplex virus immediate arly 
genes [87]. It is likely that ets proteins are involved in the 
concerted expression of OXPHOS enzymes in skeletal 
muscle in response to a work load. 
5. Aging and mitochondrial DNA mutations 
Germline and somatic human cells each contain thou- 
sands of mtDNA molecules, mtDNA is maternally inher- 
ited; somatic cells of an individual can receive from the 
mother a certain number of mutated mtDNA molecules 
mixed with normal mtDNA molecules. When these hetero- 
plasmic cells divide, the normal and mutant mtDNA 
molecules get randomly distributed into daughter cells and 
the mtDNA genotype drifts towards pure, normal or mu- 
tated (genetic segregation and tissue genetic mosaicism) 
[2,10,19,20,88,89]. Mutations of mtDNA, occurring in 
germline or somatic cells, can consist of rearrangements 
(insertions and/or  deletions) and base substitutions 
[2,20,90]. 
The mtDNA shows a much higher level of mutation 
than the nuclear genome [90,91]. This, in addition to 
reflecting the fact that cells contain thousands of copies of 
mitochondrial genes compared to only two copies of nu- 
clear genes, it could also be explained by the following 
observations: (1) mtDNA is located at the matrix surface 
Disease mtDNA mutations 
Chronic progressive external ophtalmoplegia, CPEO; Deletions between np 16 805 and 5786 (4997 bp deletion >7436 bp deletion) [2] 
Kearn Sayre Syndrome, KSS; Pearson's syndrome 
Late onset diabetes mellitus 
Alzheimer's disease and Parkinson's disease, ADPD 
Aminoglycoside-induced deafness, AID 
Leber's hereditary optic neuropathy, LHON 
Neuropathy, ataxia nd retinitis pigmentosa, NARP 
Mitochondrial encephalomyopathy lactic acidosis and 
stroke-like simptoms, MELAS 
Myoclonic epilepsy and ragged red fibers, MERRF 
Hypertrophyc cardiomyopathy and myopaty, HCM 
Lethal infantile mitochondrial myopathy, LIMM 
Fatal infantile cardiomyopathy plus, FICP 
10423 bp deletion [112] 
np 3196 in 16S rRNA [113] 
np 721 in 12S rRNA [108] 
np 1555 in 12S rRNA [114] 
np 11 778 in ND4 gene (R to H) [115] 
np 14484 in ND6 gene (M to V) [116] 
np 14459 in ND6 gene (A to V) (LDYT) [117] 
np 3460 in NDI gene (A to T) [118] 
np 15257 in cytb gene (D to N) [119] 
np 8993 in ATP6 gene (L to R or [120,12l] 
np 3243 in tRNA L [122] 
np 8344 in tRNA K [123] 
np 3260 in tRNA L [124] 
np 15923 in tRNA T [125] 
np 4269 in tRNA l [126] 
Compiled on the basis of data from Refs. given in the table. Additional diseases with different mtDNA mutations have been reported inRefs. [2,108-110]. 
For details, see Fig. 1 and text. For some of the diseases (LHON, MELAS, MERRF), in addition to those reported inthe table, other mutations have also 
been found [108-111]. 
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of the inner mitochondrial membrane where reactive oxy- 
gen species (ROS), causing oxidative damage of DNA 
[92-94], can be generated by the respiratory chain [95-97]. 
(2) Apparent absence in mitochondria of DNA-protecting 
proteins like histones [98]. (3) Mitochondria lack the ca- 
pacity to repair UV-induced pyrimidine dimers [99]; they 
seem, however, capable of repairing abasic sites [100], 
alkali-labile sites [101] and DNA oxidative damage [102]. 
The capacity to eliminate or-ethyl de-oxiguanosine ap- 
pears to be active in a replicating tissue like liver but not 
in a post-mitotic tissue like brain [103]. (4) High amounts 
in mtDNA of direct repeats [104]. Finally there is debate 
on the fidelity of the mitochondrial DNA-polimerase which 
is reported to be poor by some authors [105,106] and high 
by others [107]. 
The mtDNA undergoes a continuous turnover both in 
mitotic (epithelial cells, bone marrow cells, hepatocytes, 
etc.) and post-mitotic ells (brain, heart, skeletal muscle, 
endocrine systems, etc.) and this increases the chance of 
mutations [92,108]. In this way mutated mtDNA molecules, 
maternally inherited or produced by a mutational event in 
somatic cells, can accumulate with age in post-mitotic 
tissues. Cells harboring mutated mtDNA molecules, which 
can be few at birth, with age reach an amount which can 
impair the overall OXPHOS capacity of the tissue and 
with it the functional activity of the organ [2,19,20,108]. 
Some maternally inherited neuromuscular diseases (see 
Table 2) are associated with mtDNA rearrangements 
[2,112]. These rearrangements, resulting from a mutational 
event in the female germline cells, consist of inserted 
(duplicated) and/or deleted mtDNA molecules (see Table 
2) which are transmitted into the somatic cells together 
with normal molecules (trimolecular mtDNA hetero- 
plasmy). It has been proposed [108] that duplicated mtDNA 
molecules may be the prevailing maternally transmitted 
form of mutated mtDNA, which could be converted to 
deleted molecules [127], these undergoing clonal expan- 
sion in various tissues and zones of the same tissue [108]. 
The extent and time course by which cells harboring a 
certain percentage of deleted mtDNA molecules replace 
those with normal mtDNA with age, determines the onset, 
progression and severity of a mitochondrial disease 
[2,20,108]. 
Other neuromuscular diseases are associated with 
mtDNA base substitutions (Table 2). These base-sub- 
stituted mtDNA molecules are also maternally transmitted 
together with normal mtDNA (heteroplasmy) and expand 
clonally in various tissues and tissue zones with age. Some 
of the base substitutions can occur in structural mtDNA 
genes affecting the corresponding OXPHOS complex 
[128,129], others occur in rRNA genes [113,114] and in 
tRNA genes [122-126] and consequently have a more 
general detrimental impact on the biogenesis of the pro- 
teins encoded by the mt genome [2,20]. 
There is evidence showing that maternally inherited and 
somatic mutant mtDNA molecules are preferentially am- 
plified in post-mitotic tissues [11,20]. Whilst this explains 
why mutated mtDNA molecules accumulate with age and 
can determine OXPHOS decline, the molecular mechanism 
by which their preferential amplification takes place is 
unknown. It has been proposed that the respiratory and 
OXPHOS deficiency caused by mutated mtDNA is sensed 
by nuclei which, in response to this, try to compensate by 
upregulating replication and expression of the mutated mt 
genes [20]. Again, a critical point is represented by the 
nuclear-mitochondrial genome interaction. A role can be 
played here by the emerging myriad of protein factors, 
which encoded by the nucleus, regulate the replication and 
expression of the mitochondrial genome [37,71,130]. 
The same mutations found in the mtDNA in overt 
neuromuscular diseases can also occur in somatic cells of 
normal subjects and, for the reasons described above, they 
can accumulate with age in post-mitotic tissues. Studies 
from different laboratories show that aging is associated in
humans, exempt from mitochondrial disease, with accumu- 
lation of different deletions of mtDNA, in particular in 
post-mitotic tissues [131-136]. The common 5 kb mtDNA 
deletion, characteristic of the Kearns-Sayre syndrome, and 
the 7436 bp mtDNA deletion [2] were found in tissues of 
old subjects. The percentage of the mtDNA deletions 
accumulating with age varies substantially from tissue to 
tissue [2,131 ]. In brain basal ganglia over 10% of mt DNA 
contains the 5 kb mtDNA deletion, by the age of 80 years, 
but cerebellum accumulates a relatively small amount of 
this deletion [108]. In a study of Lezza et al. [134], the 5 kb 
mtDNA deletion in human skeletal muscle was found to 
increase exponentially from the age of 40 to 80 years, 
when it reached only a plateau of 0.3% of total mtDNA 
(Fig. 3). In this study a large individual variability in the 
percentage of the deletion was observed. Although the 5 
kb deletion never exceeded the value of 0.3%, a direct 
relationship was always found between its abundance and 
the extent of cytochrome-c oxidase deficiency [134]. The 
percentage of the 5 kb deletion appeared to be too low to 
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Fig. 3. Accumulation f common 5 kb deletion of mtDNA in human 
skeletal muscle. Linear plot of deleted mtDNA fraction i  biopsy samples 
of human skeletal muscle vs. age. Reproduced from Ref. [134]. 
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Fig. 4. Quantitative analysis of point mutations characteristic for MERRF 
and MELAS disease (see Table 2) by PCR-cycle titration in extraocular 
muscles from healthy humans of various age. Reproduced from Ref. 
[111]. 
be considered by itself a cause of the deficiency of cy- 
tochrome-c oxidase. The 5 kb mtDNA deletion could 
represent the tip of the iceberg, being indicative of multi- 
ple accompanying mutations. An involvement of defective 
nuclear genes might, however, be possible, as supported, 
in fact, by observations of Hayashi et al. [137]. This aspect 
will be further dealt with in Section 8. 
Analyses of Kadenbach et al. [111,138,139] (see also 
[140]) have shown, using a PCR method which detects 
0.1% mutated out of total mtDNA [ 141 ], that base substitu- 
tion mutations, characteristic of mitochondrial diseases, are 
also present in old control subjects (Fig. 4). These studies 
reveal the following aspects: (1) Specific base substitutions 
which are absent in young subjects accumulate xponen- 
tially with age, reaching values of 1-2% around the age of 
80 years. (2) The abundance of base substitutions shows a 
large individual variability in agreement with the multifac- 
torial characteristic of their propagation [2]. (3) The base 
substitutions characteristic of MERF (np 8344 in tRNALy~), 
MELAS (np 3243 in tRNA Leu) (Fig. 4) and chronic intesti- 
nal pseudo-obstruction (CIPO, np 10006 in tRNA Cly) were 
found in all extraocular muscles of old control subjects 
[139]. In contrast, different substitution mutations related 
to other mitochondrial diseases were not generally found 
in muscles of old control subjects [139]. This would sug- 
gest that there are sites in the mt genome which are 
particularly susceptible to mutations. 
What has been discussed leads us to conclude that aging 
is associated with accumulation i  animal tissues of rear- 
rangement and base substitution mutations of mtDNA. In 
post-mitotic tissues these age-linked mutations of mtDNA 
become particularly significant as compared to replicating 
tissues, evidently due to the fact that in mitotic cells 
normal mitochondria substitute for those which are dam- 
aged [142]. 
In senescent rats the accumulation of mutated mtDNA 
has also been found to be associated in brain and heart 
mitochondria, but not in liver mitochondria, with a reduced 
level of both the 12S rRNA and the mRNA for subunit 1 
of complex IV as compared to adult tissues [143]. Contrary 
to what was expected, the reduction in the level of these 
transcripts of mtDNA was associated with an enhanced, 
rather than decreased, copy content of mtDNA [144] (see 
also Ref. [145]). The decrease in the mtRNA content 
observed in senescent rat-brain was, in fact, linked to a 
lower efficiency of the mitochondrial transcription [146]. 
These observations would suggest hat as a compensatory 
response to defective mitochondrial biogenesis and OX- 
PHOS, senescent cells produce more copies of mtDNA, as 
it occurs in mitochondrial disease [147]. As already dis- 
cussed, mutant mtDNA molecules seem to be preferen- 
tially amplified as a possible feedback response of the 
nucleus to defective mitochondrial function. Altered 
[ATP]/[ADP]. [Pi] ratio, redox state of NAD(P) and/or 
Ca 2+ cellular homeostasis could be involved in these 
compensatory cellular loops. 
6. Ag ing  and  dec l ine  o f  OXPHOS enzymes  
From several studies carried out in various laboratories, 
it is now clearly established that in tissues of animals and 
humans there occurs an age-linked ecrease in the activity 
of mitochondrial respiratory enzymes [ 12-20,135,148] and 
FoF  ] ATP synthase [149,150]. The general decline of the 
OXPHOS capacity is associated with the appearance in
senescent tissues of marked structural changes in mito- 
chondria, like enlargement, matrix vacuolization, shortened 
cristae, etc. [151]. As only part of these damaged mito- 
chondria (light mitochondria as compared to normal heavy 
mitochondria [152]) can be recovered in the isolation 
procedure, it is possible that differences in the respiratory 
and OXPHOS capacity of mitochondria isolated from old 
versus young animals are underestimated by selective loss 
of damaged organelles. This may be one reason [153] for 
the apparent lack of age-associated biochemical changes in 
mitochondria reported by some authors [154,155]. 
In humans the most extensively screened tissue is skele- 
tal muscle due to the relative ease of obtaining biopsy 
samples from subjects exempt from clinical symptoms of 
mitochondrial diseases. The biochemical analysis of these 
samples shows that, in skeletal human muscle, aging is 
associated with decline of mitochondrial respiration 
[ 12,14-18]. An extensive pidemiological study, covering 
more than 200 control human subjects of ages varying 
from 10 to 90 years, carried out in the author's laboratory 
[17,18], has demonstrated a statistically significant age-lin- 
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ked decline of mitochondrial respiration i  skeletal muscle, 
which is associated with decrease of the activity of cy- 
tochrome-c oxidase (complex IV). No significant decrease 
with age was apparent for the activity of the ubiquinone- 
cytochrome-c oxidoreductase (bc 1, complex III), when the 
measurements for females and males were pooled together 
[17]. Later extension of the number of subjects creened 
allowed us to examine the sex dependence of age-linked 
decline of respiratory rates, specific activities of respira- 
tory chain complexes and cytochrome content in mitochon- 
dria from human skeletal muscle [18]. It seems particularly 
instructive to examine in more detail this large collection 
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Fig. 5. Statistical analysis of the activities of respiratory chain complexes in human muscle mitochondria s a function of age in males and females. 
Compiled from Refs. [17,18] and additional data from the author's laboratory (D. Boffoli, S.C. Scacco, R. Vergari, T. Persio, A. Gaballo and S. Papa, 
manuscript in preparation). For experimental procedure and details see Refs. [17,18]. 
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of data. Plots of the activity of respiratory enzymes as a 
function of age showed the measured values to be quite 
scattered, for both sexes, and at each age (Fig. 5). There is 
evidently a large variability in the genotype and phenotype 
of humans. This large variability can encompass cases of 
mitochondrial diseases which could have escaped standard 
clinical inspection. The possibility, emerging from these 
observations, is that individuals with capacities of OX- 
PHOS enzymes which are borderline with overt mitochon- 
drial disease, are relatively frequent and these cases should 
be seriously considered. These situations, which might be 
without pathological consequences under normal condi- 
tions, could result in acute crisis in the energetic apacity 
of the tissue and sudden organ failure when the individual 
attempts an intense physical effort or is put under stress. 
The variability in mitochondrial respiratory capacity can 
also reflect differences in life style, such as dietary habits, 
smoking, physical activity, exposure to infective agents 
and to toxic substances. Statistical analysis of the data, 
carried out by plotting the respiratory rates as a function of 
age, however, showed a statistically significant negative 
correlation [ 17,18]. 
Comparison of the data from males and females reveals 
a number of interesting aspects. (1) The age-linked ecline 
of respiratory rates with pyruvate plus malate, succinate 
and ascorbate plus TMPD is practically equivalent in 
males and females [17]. (2) The activity of complex IV, 
when measured by following spectrophotometrically the
oxidation of ferro-cytochrome-c, appears to decline more 
markedly in females than in males (Fig. 5). Both in 
females and males, the decline in the activity of the 
oxidase is not accompanied by any significant decrease in 
the content of heroes a+ a 3 [17,18]. Thus it cannot be 
ascribed to a depressed expression of subunit 1 of the 
oxidase, which binds the hemes and is encoded, together 
with subunits 2 and 3, by the mitochondrial genome [2,36]. 
(3) The activity of the bc~ complex, (Fig. 5), as well as the 
content of cytochrome b [18] in the skeletal muscle of 
females, exhibit a marked decrease with age that is not 
observed in males. 
Cytochrome b is the first largest protein of the three 
conserved subunits of bc 1 complexes [156]. In the mam- 
malian enzyme, which is made up of 11 subunits [157], 
cytochrome b is the only one to be encoded by the 
mitochondrial genome [26,158]. The structural gene coding 
for cytochrome b is located in the heavy (H) strand of 
mtDNA, near the major control region delineated by the 
displacement D-loop and is affected in some mtDNA 
deletions observed in human neuromuscular diseases (see 
Fig. 1 and Table 2). The decline observed in females with 
aging, together with the observation that the activity of the 
bc~ complex is in young females ignificantly higher than 
in young males, would indicate that the content of cy- 
tochrome b in mitochondria nd of an active bc~ complex 
is directly or indirectly controlled by females sex hor- 
mones. Related to these observations eems to be the 
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Fig. 6. Statistical analysis of the ATP hydrolase activity in human muscle 
mitochondria as a function of age. Compiled from data from the author's 
laboratory (D. Boffoli, S.C. Scacco, R. Vergari, T. Persio, A. Gaballo and 
S. Papa, manuscript in preparation). For experimental procedure see Ref. 
[1681. 
finding that the physiologically altered function of the 
human ovary during menopause is accompanied by an 
accumulation of deleted mtDNA in the ovary [159]. 
As mentioned in Section 1, the central nervous system 
derives its energy almost exclusively from OXPHOS, and 
deficiency of this process is likely to have a severe patho- 
logical effect on this tissue. It has been proposed that CNS 
degenerative diseases, like Alzheimer's disease [108,113], 
Parkinson's disease, Huntington's disease, heart degenera- 
tive disease, late onset diabetes mellitus, which affect 
humans in their late years, are associated with OXPHOS 
decline [2,108,160,161]. 'In vivo' analysis of OXPHOS 
enzymes in these tissues, in the course of aging, is practi- 
cally impossible. The difficulty can be circumvented at 
least in some cases by analysis of respiratory activities in 
blood cells like platelets and by in vivo spectroscopic 
3L P-NMR (see Section 9). 
More recently, the author's group has initiated a screen- 
ing of the activity of the mitochondrial F o F l ATP synthase 
(complex V) in human skeletal muscle in control subjects 
of different ages. The data collected show that the activity 
of the ATP synthase, measured as ATP hydrolase (Fig. 6), 
decreases significantly with aging. 
The measurement of the activities of the OXPHOS 
complexes is human skeletal muscle is now being ex- 
tended, in our laboratory, to a simultaneous semiquantita- 
tive analysis of their content and polypeptide composition 
using the blue-native, non-denaturating, two-dimensional 
electrophoresis procedure developed by Schiigger et al. 
[162-164]. 
Studies of Guerrieri et al. [149,150,165] have shown 
that in rat-heart and rat-brain mitochondria, the content and 
the activity of the FoF j ATP synthase first increases, 
going from young to adult animals, and then sharply 
declines with aging. Age-linked changes in the content and 
activity of the ATP synthase were also found in rat-liver 
mitochondria [166,167], although these were much less 
marked than those observed in heart and brain mitochon- 
dria [149,150]. The content and activity of the ATP syn- 
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thase change also in the course of liver regeneration. Both 
decrease in the first hours after hepatectomy, than return to 
control levels when the liver regains the initial mass 
[ 166-168]. The mRNA transcript of the [3 F 1 subunit, on 
the contrary, shows only some increase in the latter phase 
of liver-regeneration [167]. The initial decline of the ATP 
synthase, rather than being due to a depressed transcrip- 
tion, could be associated with enhanced proteolytic degra- 
dation triggered by reactive oxygen species [169]. 
7. OXPHOS and oxygen free-radical balance 
Sustained oxidative damage of nucleic acids, proteins 
and lipids caused by reactive oxygen species (ROS), is 
considered to be a major factor in the general functional 
decline of tissues associated with aging and age-associated 
degenerative diseases like cardiovascular diseases, CNS 
dys funct ions ,  im m une-sys tem dec l ine  
[142,153,159,160,170-172] and cancer [173]. It has been 
calculated that ROS are responsible for around 10000 
DNA base oxidative modifications per cell per day and it 
is quite conceivable that a finite fraction of these damages 
escapes repair by the array of cellular defense mechanisms 
[171,172]. 
The respiratory chain, particularly under certain 
physio-pathological onditions, is responsible for most of 
the ROS produced in human tissues [95]. Mitochondrial 
respiration accounts for about 90% of cellular oxygen 
uptake and 1-2% of the oxygen consumed is converted to 
ROS [95]. ROS are also produced by cytochrome P450 and 
cytosolic soluble oxidases particularly in the presence of 
oxidant producing drugs [174]. Oxygen superoxide, 0 2 is 
generated by complexes, I II and III of the respiratory 
chain [95-97,175] but not by cytochrome-c oxidase which 
seems, on the other hand, to display SOD activity itself 
[176] (Fig. 7). 6 2 production by complexes I, II and III is 
promoted when the supply of respiratory substrates, de- 
rived from food, exceeds the energy demand. Under these 
conditions the phosphate potential ([ATP]/[ADP] [Pi]) is 
high, aerobic AOM + in mitochondria depresses respiration 
(State 4), the electronegativity of autooxidizable redox 
carriers in complexes I, II and III and cellular oxygen 
tension rise with consequent enhanced ROS production 
[95,177]. The autoxidizable redox intermediates in com- 
plexes I and II are flavin radicals, nonheme iron and 
semiquinone radicals, the latter two species are also formed 
in complex III [96,178]. The level of these reactive reduc- 
tants and hence of ROS can be enhanced by defects in 
respiratory complexes or by inhibitors of complex III, like 
antimycin [96,178], or of complex I like rotenone [175] or 
neurotoxic meperidine analog derivatives MPTP and MPP + 
[179-181] (see, however, Ref. [182]) which cause Parkin- 
sonism-like symptoms [183]. 6~- produced at the cytosolic 
surface of the inner mitochondrial membrane can be oxi- 
dized by cytochrome c, cytochrome-c oxidase or con- 
verted to H20 2 by the cytosolic Zn-SOD. 6 f  produced at 
the matrix side is essentially converted to H202 by the 
Mn-SOD of the matrix [184] (Fig. 7). In both the matrix 
and cytosol H202 is reduced to H20 by glutathione 
peroxidase [185]. H20 2 which diffuses to peroxisomes i
cleaved there by catalase to H20 and 02 [186]. Further- 
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more, ROS are scavenged by vitamins C and E and 
ubiquinone. The excess H20 2 is converted in the presence 
of Fe 2÷ to OH by the Fenton reaction [187]. The OH 
radical is extremely reactive and produces oxidative dam- 
age of lipids, nucleic acid and proteins [171]. 
With age, the fluidity of cell membranes, including the 
mitochondrial one, decreases and this is associated with 
enhanced lipid peroxidation [188]. The linolenic acid con- 
tent of mitochondrial lipids, in particular of cardiolipin, 
decreases with increase in more polyunsaturated fatty acids 
which are more sensitive to oxidation reactions [188]. 
Cardiolipin oxidative damage is particularly deleterious as 
this phospholipid seems to be required for the activity of 
mitochondrial enzymes [ 189,190] and metabolite transloca- 
tors [191]. Membrane damage caused by lipid peroxidation 
can be repaired by phospholipase A 2. This enzyme re- 
moves oxidized lipids from membranes [192] and its activ- 
ity increases under conditions of oxidative stress [193]. 
Recent availability of adequate analytical methods has 
made it possible to determine oxidative damage of nucleic 
acids [92,94,153,194-196]. It has been found that levels of 
oxidative damage of mtDNA from rat-liver and human 
brain are several fold higher than those of nuclear DNA 
[92,196]. A direct marker of oxidative damage of DNA is 
represented by the conversion of dG to 8-OH-dG [196]. 
Analysis on mtDNA hydrolysate from human myocardium 
autoptic samples howed that in normal subjects the con- 
tent of 8-OH-dG was undetectable up to the age of 40, 
then started to increase exponentially with age to reach 
1.5% of dG residues at 90 years [94] (Fig. 8). Accumula- 
tion of 8-OH-dG in DNA could trigger double-strand 
separation which favors DNA deletions. A clear correla- 
tion between the accumulation of 8-OH-dG in mtDNA and 
mtDNA deletion was, in fact, observed in the myocardium 
of aging human subjects (Fig. 8) [94]. 8-OH-dG in mtDNA 
has also been detected in the diaphragm muscle (0.5% of 
dG residues) [195] and in brain (0.8%) of 85- to 90-year-old 
human subjects [196]. 
Oxidative damage of mitochondrial proteins with for- 
mation of reactive carbonyl groups has been found to 
increase with age [171]. These oxidized proteins could 
undergo cross-linking, proteolysis and loss of functional 
activity. As previously mentioned in rat heart and brain, 
aging has been found to be associated with decrease in 
mitochondria of the content of the 13 F1 subunit and depres- 
sion of the catalytic activity of the F oF l ATP synthase 
[149,150]. The same decrease in content and activity of the 
ATP synthase was observed when the formation of the 
OH. radical was promoted by exposing the isolated mito- 
chondrial membrane to Co irradiation [ 165]. 
The enhanced oxidative damage of lipids, proteins and 
nucleic acids in mitochondria observed in aged humans 
(and animals) indicates that the balance between ROS 
production and scavenging is altered in the course of aging 
so as to result in a progressive age-linked enhancement in 
the steady-state l vel of ROS in the cell, particularly in 
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mitochondria, and/or enhanced sensitivity to ROS of 
DNA, proteins and lipids. Oxidative damage of mtDNA 
can lead to mtDNA mutations and this to defective OX- 
PHOS enzymes. Defects in respiratory enzymes deriving 
from mtDNA mutations and/or nuclear DNA mutations, 
or directly from oxidative damage of the enzyme proteins 
and associated lipids can, on their part, lead to enhanced 
Environmental 
or genetic ~N~ 
factors 
mtDNA deletions ROS 
Fig. 9. Vicious cycle for ROS production, mtDNA deletion and cy- 
tochrome-c oxidase defect in aging. 
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ROS production. In particular, a defect of cytochrome-c 
oxidase (this enzyme contributes to lower the level of ROS 
[176]), relative to complexes I, II and III which produce 
ROS, can contribute to enhance ROS level, which in turn 
will cause more mtDNA damage. Thus, a vicious cycle 
can set up which will produce progressive damage of the 
OXPHOS system (Fig. 9). 
8. OXPHOS decline, bioenergetic threshold and apop- 
tosis 
Aging in humans is characterized by decrease in the 
mass and functional capacity of brain, heart, skeletal mus- 
cle and other post-mitotic tissues, in particular those hav- 
ing a high demand for OXPHOS [2]. Evidence was re- 
viewed in Section 7 indicating that a major effector of 
tissue aging is given by oxidative damage of lipids, pro- 
teins and DNA. mtDNA is particularly sensitive to oxida- 
tive damage, this contributing to age-linked accumulation 
of mtDNA mutations. We have seen in Section 6 how 
OXPHOS capacity declines with age, particularly in post- 
mitotic tissues. However, these observations raise a num- 
ber of questions which, at present, can only be partially 
answered. (1) To what extent mtDNA mutations determine 
the age-linked decrease of OXPHOS; (2) to what extent 
this decrease is involved in the decline of post-mitotic 
tissues; (3) are there other events triggered by ROS which 
can play a determining role in the age-linked ecline of 
these tissues? 
Rearrangement and base substitution deletions accumu- 
late exponentially with age particularly in post-mitotic 
tissues [2,88,94,111 ]. Studies on cell cultures show that an 
impairment of energy metabolism is observed only at 
above 60-90% of mutated mtDNA [111,197-199]. The 
onset of clinical symptoms in MERRF patients was ob- 
served above 90% of mutated mtDNA [200,201]. The 
percentage of the single mtDNA mutations which accumu- 
late with age, as for example the 5 kb deletion seem to 
reach significant values in brain, basal ganglia and cortex 
by the age of 80 [108]. If the 5 kb deletion is accompanied 
by other mutations, then the total level of mtDNA muta- 
tions could reach the critical threshold with impairment of 
OXPHOS. Under these conditions, it is quite likely that in 
the brain tissues, which can present a mosaicism of cells 
with different abundance of mutated mtDNA, those cells 
which reach the critical threshold of mtDNA mutations 
start to be functionally compromised and there will occur a 
progressive reduction in the overall nqmber of cells and 
functional brain decline. This situation, which is likely to 
arise from extensive oxidative damage of mtDNA, might 
in fact be peculiar to dopaminergic neurons which have a 
high content of monoamine oxidase, an enzyme producing 
hydrogen peroxide [181,182]. 
The situation seems to be different in the skeletal 
muscle. The studies on human biopsies of human subjects 
have shown that the 5 kb deletion accumulates exponen- 
tially with age but it levels off at the age of 80-90 years at 
a level of only 0.3% (see Section 5) [134]. The respiratory 
rates with different substrates and the activities of redox 
complexes and ATPase decline, on the other hand, linearly 
and markedly with age [17,18]. This would suggest hat 
other factors can be involved in the age-dependent decline 
of mitochondrial respiratory enzymes. Direct oxidative 
damage of the protein subunits of respiratory enzymes and 
of ATP synthase might play a role. 
Cytochemical and in situ hybridization studies on ex- 
traocular muscle fibers in old subjects show that most of 
the fibers which presented focal-segmental defects of cy- 
tochrome-c oxidase, exhibited a normal hybridization pat- 
tern for mtDNA, this indicating the contribution in the 
deficiency of the oxidase of nuclear factors [202]. By 
means of intercellular transfer of mtDNA and nuclear 
genome in cultures of human fibroblasts and mt-DNA less 
Hela cells, Hayashi et al. [137] have produced results 
indicating that the nuclear genome is involved in the 
age-linked ecline of cytochrome-c oxidase in human fi- 
broblasts. Another possible difference between brain cor- 
tex and muscle in their response to mtDNA deletions and 
OXPHOS decline could be represented by a different 
critical OXPHOS threshold, higher in brain cortex and 
other nerve cells as compared to muscle cells, so that, due 
to the age-linked ecline, OXPHOS capacity falls below 
the threshold earlier in nerve cells as compared to muscle. 
Normal development and differentiation of multicellular 
organisms require controlled cell proliferation and death. 
Alterations in the controlled balance of cell proliferation 
and/or death appear to be critical in neoplastic prolifera- 
tion [203-205]. Alteration in the control of cell death may 
also be involved, on the other hand, in age-linked cell 
mass reduction and degeneration of post-mitotic tissues. 
Gene directed programs of cell death (PCD) have been 
identified in different tissues [206,207]. PCD can be in- 
duced by diverse stimuli. However, these appear to acti- 
vate a common program of biochemical and morphological 
events, which is apoptosis [206-208]. In the apoptotic 
death, cells undergo transition from a normal state into 
successive shrunken forms with reduction of their volume 
without detectable release of their constituents [206]. The 
shrunken apoptotic remnants are then phagocytosed by 
macrophages and their constituents recycled [209]. 
Apoptosis is promoted by activation of endogenous 
factors like the cytokine tumour necrosis factor (TNF), the 
anti-FAS antibody/FAS antigen, sulphated glycoprotein-2, 
glucocorticoid receptor [210-213] and by exogenous tim- 
uli like cortico-steroid treatment, exposure to ionizing 
radiation or to exogenous ROS or ROS producing sub- 
stances [205,214]. 
Apoptosis is blocked by overexpression of the Bcl-2 
protein, whose gene (protooncogene) was discovered at the 
t (14,18) chromosomal breakpoint in human follicular 
lymphomas [215]. The Bcl-2 protein is primarily localized 
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TNF 
/ . ~  Apoptosia 
BAX- .~ ? ~,  
ROS / ~ death 
OXPHOS 
mutations ~ defects 
Fig. 10. Possible mechanisms for involvement of ROS, apoptosis, DNA 
mutations and OXPHOS defects in age-linked cell death. The thin lines 
indicate additional hypothetical pathways. 
in the inner mitochondrial membrane [216-218], but it has 
also been found in endoplasmic reticulum and nuclear 
membrane [219,220]. The Bcl-2 protein can form homod- 
imers or heterodimers in the membrane with another pro- 
tein, BAX (Bcl-2 associated x protein) [218]. Evidence has 
been obtained indicating that in normal conditions Bcl-2 
and BAX are present in the membrane as heterodimer 
[218]. When Bcl-2 is overexpressed, Bcl-2 homodimers 
dominate and cells are protected against death. When BAX 
is in excess, BAX homodimers dominate and cells can 
undergo apoptosis [205,218]. 
A possible role of apoptosis in the age-linked reduction 
of the mass of post-mitotic tissues [181] can, in principle, 
be reconciled with the proposed role of OXPHOS defi- 
ciency in tissue aging [2,108]. Various observations point 
to a relationship among apoptosis, mitochondrial damage 
and tissue aging. A link among these processes can in fact 
be provided by ROS [205,208,214,221]. The role of ROS 
in mitochondrial damage has already been discussed (Sec- 
tion 7. Continuous exposure of cells to low levels of 
oxidants seems to trigger apoptosis rather than necrosis 
[214]. Increasing doses of oxidants progressively result in 
cell proliferation, apoptosis and necrosis [214,221,222]. 
Antioxidants have been found to prevent apoptosis induced 
by TNF, antiFAS/FAS and drugs [221-225]. 
From what has been discussed, the following picture 
can be outlined (Fig. 10). As age advances, progressive 
imbalance between ROS production and scavenging results 
in enhanced cellular ROS levels with continuous exposure 
of cell structures to oxidative damage. This seems to result 
in activation of apoptosis factors, which can take place at 
gene structure/expression and/or protein level. Apoptosis 
can be counteracted by enhanced expression of the Bcl-2 
protein. The action of Bcl-2 could, however, be itself 
impaired by progressive oxidative damage. Activation of 
apoptosis promoters like TNF can contribute to further 
increase in ROS production [225-227]. Enhancement of 
ROS cellular concentrations above a critical level and 
consequent significant oxidative damage of DNA (prim- 
arily mtDNA) lead to progressive accumulation of DNA 
deletions and impairment of the activity of respiratory 
chain complexes and ATP synthase. Cells undergoing 
apoptosis exhibit a decrease in the mitochondrial aerobic 
A~H + [228], indicative of OXPHOS deficiency, and de- 
pression of the translation of subunits of cytochrome oxi- 
dase and F oFj ATP synthase ncoded by mtDNA [229]. 
This depression in mitochondrial translation is of nuclear 
origin, since the level of mtDNA is apparently unaffected 
[229]. Deficiency of respiratory complexes will contribute 
to further enhance ROS production and thus the vicious 
cycle already discussed is set up (Fig. 9). Decrease of the 
respiratory rate results in enhancement of cellular oxygen 
tension which, in combination with enhanced levels of 
autooxidizable r ductants, enhances ROS production, with 
accumulation of DNA oxidative damage and mutation, 
OXPHOS deficiency, activation of apoptosis [230]. Thus, 
with aging, activation of apoptosis and decline of OX- 
PHOS can converge in causing cell death. This cyclic 
combination of events can be inhibited at various points by 
the array of cellular defense systems involved in protein, 
lipid and DNA repair. Oxidative damages can also be 
counteracted by exogenous antioxidants like, vitamin E, 
vitamin C, lipoic acid, etc. These substances are already 
taken up in good amounts with a balanced iet and can be 
administered in appropriate doses and combinations when 
their needs are increased. 
Severe prolonged eficiency of vitamin E in man gives 
rise to a well-characterized neurological syndrome [231] 
and, although less studied, to a myopathy [232]. Vitamin E 
deficiency also causes a neuromuscular syndrome in rats 
[232,233]. This has been shown to be associated with 
muscle fibre necrosis, reduced mitochondrial membrane 
fluidity, possibly secondary to lipid peroxidation, and sig- 
nificant decrease of the activities of complexes I and IV 
[234]. 
9. In vivo monitoring of OXPHOS capacity 
Non-invasive spectroscopic techniques have been devel- 
oped in the last years and are now used for in 'vivo' 
monitoring of the bioenergetics of human organs [235- 
238]. The most widely used of these techniques, and the 
one giving the more relevant information, is the 3~ P-nuclear 
magnetic resonance spectroscopy (NMRS) which provides 
direct 'in vivo' measurement of the concentrations of Pi, 
phosphocreatine, ATP, hexose-mono and diphosphates and 
intracellular (cytosolic) pH in human organs, skeletal mus- 
cle in the first place, but also brain, heart, liver, etc. [235]. 
3~P_NMR spectra of skeletal muscle can be taken at 
rest, during exercise and in the recovery phase [235,236]. 
At rest, steady-state concentrations of P~, Pcr, ATP and 
hexose phosphates reflect the basal energy expenditure for 
hormonally controlled transport processes and can be of 
use in exploring the function of endocrine systems and 
kidney [239,240]. 
In the resting human skeletal muscle, typical concentra- 
tions of phosphoryl compounds are 4 mM [ATP], 0.01 mM 
[ADP], 25 mM [Phosphocreatine] and 13 mM [Creatine] 
[235]. Phosphocreatine r presents the major reservoir of 
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high potential phosphoryl groups in skeletal muscle, due to 
the high concentration of creatine and the high activity of 
creatine kinase which transfers the phosphoryl group from 
ATP, produced in excess of the energy demand, to crea- 
tine. During exercise, the concentration of phosphocreatine 
drops dramatically to rise again in the recovery phase. This 
recovery is directly relevant for 'in vivo' evaluation of the 
OXPHOS capacity since the contribution of glycogeno- 
lysis for ATP production, which can be significant during 
exercise, is shut during the recovery and ATP is entirely 
produced by OXPHOS [236]. The post-exercise initial rate 
of phosphocreatine recovery provides a measure of the rate 
of ATP production 'in vivo' by OXPHOS. The rate of 
mitochondrial ATP synthesis by OXPHOS (Q), obtained 
from the measured rate of phosphocreatine recovery, shows 
a saturation dependence on the ADP concentration at the 
end of exercise. This relationship is described by the 
equation: 
Q = Qmax/(l + Km/[ADP])  
which can be used to calculate Q at half maximal [ADP] 
and the maximum rate value (Qmax) which amounts to 
about 40 mmol/1 cell water per min. The concentration of
ADP and hence the rate of aerobic ATP synthesis and the 
phosphorylation potential ([ATP]/[Pi][ADP]) can easily be 
calculated from the equilibrium constant of the creatine 
kinase reaction once the concentrations of Pi, phosphocrea- 
tine and ATP are determined by 3~ P-NMR spectra [236]. 
Using these procedures, the 'in vivo' phosphorylation 
potential in the resting human skeletal muscle and maxi- 
mal capacity (Qmax) of OXPHOS in the post-exercise 
recovery, together with H + clearance, have been measured 
by 31p-NMR spectroscopy in a large number of normal 
subjects and patients diagnosed or suspected of mitochon- 
drial myopathies [235,236]. These studies have contributed 
to define a number of abnormalities of energy metabolism 
which characterize OXPHOS deficiencies [235,236,241]. 
In nearly all patients affected by mitochondrial my- 
opathies, human skeletal muscles (flexor digitorum super- 
ficialis, gastrocnemius), showed a low phosphorylation 
potential at rest and, more significantly, a slow recovery of 
phosphocreatine and decreased Qmax of OXPHOS. This 
was accompanied by faster H + clearance (recovery from 
cytosolic acidosis) and increase in [ADP], which in part 
compensates in defective mitochondria for the decreased 
Qmax [235]. 
Examination of these parameters by 3~p-NMR spec- 
troscopy in healthy subjects over wide age ranges has 
produced apparently contrasting results. While a study 
showed a decrease of 'in vivo' OXPHOS capacity in 
skeletal muscle of aging human subjects [242], another 
study did not reveal any age-dependent impaired 'in vivo' 
OXPHOS function in old subjects, as judged from practi- 
cally unchanged values of Q . . . . .  of OXPHOS [243]. Whilst 
the causes for these different findings are not clear at 
present, it would be important to standardize the measuring 
conditions. 31p-NMR spectroscopy in combination with 
other 'non-invasive' spectroscopic techniques (like near- 
infrared spectroscopy, NIRS [238]), morphometric and er- 
gometric analysis of muscle mass and strength, inspection 
of heart and CNS function, and imaging NMR for less 
accessible organs like brain, liver, etc., can provide an 
ultimate 'in vivo' assessment of the impact of OXPHOS 
deficiency on the functional activity of tissues, life quality 
and life expectancy in aged subjects. 
10. Conclusions 
OXPHOS undergoes definite changes in the life span of 
animals and humans. The first is observed in the transition 
from fetal to neonatal life (adaptation to aerobic life). This 
change involves complex up-regulation of co-ordinate 
mitochondrial biogenesis. Opposite changes in the pattern 
and activity of OXPHOS enzymes seem to occur in the 
malignant transformation f cells. 
The biogenetic and catalytic activity of mitochondria 
are able to adjust the capacity of OXPHOS to the continu- 
ously changing energy demand, as shown by up-regulation 
of mitochondrial biogenesis and function in response to 
exercise in muscle. 
With aging DNA mutations, particularly in the mito- 
chondrial genome, accumulate, mtDNA mutations eem to 
be primarily caused by ROS whose cellular level increases 
as a consequence of imbalance between their production, 
mainly in mitochondria nd scavenging. Accumulation of 
DNA mutations, possibly in combination with direct oxida- 
tive damage of protein subunits of redox complexes and 
ATP synthase, result in the age-linked general decline of 
the OXPHOS capacity of post-mitotic tissues. Age-linked 
enhancement of ROS cellular level can induce apoptosis. 
Apoptotic cell death involves activation of the mitochon- 
drial BAX protein, which can be blocked by the mitochon- 
drial Bcl-2 protein. A study of the effect of ROS on the 
expression and activity of these two proteins would be 
highly desirable. The age-linked impairment of OXPHOS 
can activate apoptosis through enhancement of the cellular 
level of ROS or by some other mechanism. OXPHOS 
deficiency can thus lead to apoptotic or different forms of 
cell death. 
Development, physiological adaptation, transformation 
and aging appear to rely on the 'switching on and off' of 
certain critical nuclear genes (and protooncogenes) which 
also affect mitochondrial biogenesis. A particular ole can 
be played, in this respect, by the ets proteins, NRF-1 and 
NRF-2, BAX and Bcl-2 and TNF. The relationships be- 
tween these factors, oxidant/antioxidant balance, amplifi- 
cation of mtDNA mutations, OXPHOS defects, apoptosis 
and their impact in the age-related ecline of human 
beings, will also attract much interest, especially in consid- 
eration of the prolonged life-expectancy of humans. 
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